General Information Regarding Paper and Poster Abstracts
The ASPHO Program Committee invites the submission of abstracts for papers and posters to be presented at ASPHO’s 26th Annual Meeting, April 24–27, 2013, in Miami, FL.
The system will remain open from October 29, 2012, to January 7, 2013. The system will close at 11:59 pm Pacific Time on January 7, 2013, and additional submissions will not be accepted.
Primary authors will be notified in February 2013 regarding selection of their abstracts.
This is an electronic submittal system. The system is compatible with PCs and Macintosh computers.
The goal of the ASPHO Program Committee is to solicit the very best original, basic, clinical, and social science abstracts that relate to the field of pediatric hematology/oncology. It is understood that any individual abstract may be part of an ongoing project. Paper and poster abstracts previously presented or published in whole or in part may be submitted. Abstracts should be updated or modified in some way.
Authors should please note: ASPHO has always allowed previously presented work (e.g., a platform talk presented at the American Society of Hematology meeting in December of the year prior to the ASPHO spring meeting) to be presented at ASPHO meetings. Many societies do not allow such double presentations, so authors are encouraged to verify the rules for any meeting that may occur after the ASPHO annual meeting. Material that has been or is expected to be published in manuscript form before the dates of the ASPHO meeting is not acceptable for presentation in either poster or platform formats.
Case reports are acceptable as abstracts, but authors should be aware of the following:
Important Information About Submission and Issues Related to Copyright
The primary author will be asked to sign an Abstract Submission Agreement, which confirms that the primary author agrees to grant ASPHO unrestricted, irrevocable permission to publish the abstract in printed materials, in a searchable database, and as a PDF file. The primary author retains the abstract’s copyright, and anyone wishing to use the abstract after the ASPHO meeting will be instructed to contact the primary author for permission.
Paper and poster abstracts will be presented during concurrent session time blocks throughout the annual meeting. Posters will be presented on either Thursday, April 25, or Saturday, April 27. Presentation times will be assigned at the time the abstract is accepted; authors cannot request a specific presentation date and time. Prior to submission of a paper or poster, at least one author must agree to attend the ASPHO meeting and to participate as the paper or poster presenter. ASPHO will not waive the registration fee for presenters. Presenters are responsible for all personal expenses (e.g., travel, hotel) and for conference registration fees. Presenters are encouraged to register for the meeting and to reserve hotel accommodations as early as possible to ensure that space is available.
Policy on Commercial Support
Presentations must avoid commercialism and should conform to accreditation standards for commercial support. Presentations that constitute promotion and advertising will not be accepted, including pervasive or inappropriate use of logos. Company product information may not be displayed or disseminated in conjunction with the presentation. If the author(s) received any funding for this research, a clear acknowledgment of support should be included at the end of the abstract (e.g., Supported by a grant from ABC Pharmaceuticals).
Paper and poster submissions will be reviewed and rated by members of the Program Committee who have expertise in the research or clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, and study design.
ASPHO does not allow late-breaking abstracts. All submissions must be received by the January 7 deadline.
An alphabetical list of primary authors’ names will be posted on the ASPHO website in February. This will be the first opportunity to learn whether an abstract was accepted or rejected for presentation and in what format.
All communications will be directed to the primary author. If the primary and presenting authors are different, communication will continue through the primary author. It is the responsibility of the primary author to communicate with the presenting author. The presenting author must be a coauthor on the abstract.
Primary authors on paper submissions will be notified by e-mail in February of their abstract’s acceptance or rejection. All authors on submissions considered for paper presentation will be required to complete a disclosure form; details will be included with the notification letter.
Primary authors on poster submissions will be notified by e-mail in February of their abstract’s acceptance or rejection.
Click here to begin your paper or poster abstract submission or to retrieve or edit an existing submission.
Please contact ASPHO at 847.375.4716 if you need assistance with your submission. Our staff is available to assist you Monday–Friday, 8 am–6 pm Central Time.